An update from Contineum Therapeutics, Inc. Class A ( (CTNM) ) is now available.
On March 14, 2025, Contineum Therapeutics, Inc. appointed Diego Miralles, M.D. to its Board of Directors as a Class II director, with his term expiring at the 2026 annual meeting of stockholders. Dr. Miralles, who has extensive experience in the pharmaceutical and biotechnology sectors, was previously engaged with the company under an advisor agreement that provided strategic, scientific, and clinical development consulting services. His appointment is part of the company’s ongoing efforts to strengthen its leadership team. Dr. Miralles will receive compensation as a non-employee director, including an initial grant of stock options, and has entered into an indemnification agreement similar to those of other board members.
More about Contineum Therapeutics, Inc. Class A
YTD Price Performance: -53.94%
Average Trading Volume: 80,811
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $172.6M
For a thorough assessment of CTNM stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com